Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Fresenius Medical Care AG & Co. KGaA FMS

Healthcare  —  Medical Care Facilities
22.69 0.34 1.52% as of 25 Sep
Market cap
$11.9B
P/E
11.8×
Dividend Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Fresenius Medical Care AG & Co. KGaA (FMS) Business Profile

Updated before January 2025

Company Overview

Fresenius Medical Care AG & Co. KGaA (FMS) is a global leader in providing products and services for individuals with chronic kidney failure. The company was founded in 1996 as a result of the merger between Fresenius Worldwide Dialysis and National Medical Care. Headquartered in Bad Homburg, Germany, FMS operates in over 150 countries and employs more than 120,000 people worldwide. The company is listed on the Frankfurt Stock Exchange and the New York Stock Exchange, reflecting its global presence and investor interest.

FMS is led by a team of experienced executives. As of 2023, the CEO is Helen Giza, who has extensive experience in healthcare and finance. The company’s leadership team is committed to innovation, patient care, and sustainability, ensuring that FMS remains at the forefront of the renal care industry.

Core Business Segments

Fresenius Medical Care operates through two primary business segments: Products and Services.

Products

FMS offers a comprehensive range of products designed to support dialysis treatment. These include:

  • Dialysis Machines: Advanced machines that perform hemodialysis and peritoneal dialysis, ensuring effective treatment for patients with kidney failure.
  • Dialyzers: High-quality filters used in dialysis machines to remove toxins and excess fluids from the blood.
  • Disposables: A wide range of single-use products, such as bloodlines, needles, and catheters, essential for dialysis procedures.
  • Water Treatment Systems: Equipment that ensures the purity of water used in dialysis, a critical component of patient safety.

Services

FMS is the largest provider of dialysis services globally, operating a network of over 4,000 dialysis clinics. These clinics offer:

  • In-Center Hemodialysis: Treatment provided in a clinical setting under the supervision of healthcare professionals.
  • Home Dialysis: Support and equipment for patients who prefer to undergo dialysis in the comfort of their homes.
  • Chronic Kidney Disease (CKD) Management: Comprehensive care programs aimed at slowing the progression of kidney disease and improving patient outcomes.
  • Value-Based Care Models: Innovative payment and care delivery models that focus on improving patient outcomes while reducing healthcare costs.

Business Model

Fresenius Medical Care’s business model is built on vertical integration, combining products and services to deliver comprehensive care for patients with kidney failure. The company manufactures dialysis equipment and supplies, which are then used in its own clinics or sold to external healthcare providers. This integrated approach allows FMS to maintain high standards of quality and efficiency while generating revenue from both product sales and service delivery.

FMS also leverages its global scale to optimize operations and reduce costs. By investing in research and development, the company continuously innovates its product offerings and improves patient care. Additionally, FMS collaborates with healthcare providers, payers, and policymakers to develop value-based care models that align incentives and improve outcomes.

Strategic Direction

Fresenius Medical Care is focused on several strategic priorities to drive future growth:

  • Expansion of Home Dialysis: The company aims to increase the adoption of home dialysis by providing advanced equipment, training, and support for patients and caregivers.
  • Digital Transformation: FMS is investing in digital health solutions, such as telemedicine and data analytics, to enhance patient care and operational efficiency.
  • Sustainability Goals: The company is committed to reducing its environmental footprint by improving energy efficiency, minimizing waste, and adopting sustainable practices across its operations.
  • Geographic Expansion: FMS plans to strengthen its presence in emerging markets, where the prevalence of kidney disease is rising and access to care is limited.
  • Innovation in Products and Services: The company continues to invest in R&D to develop new technologies and treatment modalities that improve patient outcomes.

Competitive Landscape

Fresenius Medical Care faces competition from several companies across its product and service segments. Key competitors include:

  • DaVita Inc.: A leading provider of dialysis services in the United States.
  • Baxter International Inc.: A global healthcare company that offers dialysis products and therapies.
  • Nipro Corporation: A Japanese company specializing in medical devices, including dialysis equipment.
  • Medtronic: A multinational medical technology company with a presence in renal care.
  • Local and Regional Providers: Smaller companies and healthcare providers that operate in specific markets.

Despite the competitive landscape, FMS maintains a strong market position due to its scale, integrated business model, and commitment to innovation.

Risk Factors

Fresenius Medical Care faces several risks that could impact its business:

  • Regulatory Changes: Changes in healthcare regulations and reimbursement policies could affect the company’s revenue and profitability.
  • Market Dependence: A significant portion of FMS’s revenue comes from dialysis services, making it vulnerable to changes in demand or competition in this market.
  • Supply Chain Disruptions: The company relies on a global supply chain for its products, which could be affected by geopolitical tensions, natural disasters, or other disruptions.
  • Economic Conditions: Economic downturns or changes in healthcare funding could impact patient access to dialysis treatment.
  • Technological Advances by Competitors: Innovations by competitors could erode FMS’s market share if the company fails to keep pace.

Recent Developments

In recent years, Fresenius Medical Care has made significant strides in innovation and corporate strategy:

  • Launch of New Dialysis Machines: The company introduced advanced dialysis machines with improved efficiency and patient comfort.
  • Partnerships for Value-Based Care: FMS has entered into partnerships with healthcare providers and payers to implement value-based care models.
  • Sustainability Initiatives: The company has set ambitious targets for reducing greenhouse gas emissions and improving resource efficiency.
  • Response to Global Events: During the COVID-19 pandemic, FMS adapted its operations to ensure the safety of patients and staff while maintaining continuity of care.

Investment Considerations

Investors considering Fresenius Medical Care should weigh the following factors:

Strengths

  • Market Leadership: FMS is the largest provider of dialysis products and services globally.
  • Integrated Business Model: The company’s vertical integration enhances efficiency and quality control.
  • Commitment to Innovation: Continuous investment in R&D ensures a competitive edge.
  • Global Presence: Operations in over 150 countries provide diversification and growth opportunities.

Risks

  • Regulatory and Market Dependence: Changes in healthcare policies or market dynamics could impact revenue.
  • Economic Sensitivity: The company’s performance is influenced by economic conditions and healthcare funding.
  • Competition: Intense competition in the dialysis market could pressure margins.

Conclusion

Fresenius Medical Care AG & Co. KGaA is a global leader in renal care, offering a comprehensive range of products and services for patients with chronic kidney failure. The company’s integrated business model, commitment to innovation, and strategic priorities position it for continued growth. While FMS faces risks such as regulatory changes and competition, its market leadership and focus on sustainability make it a compelling choice for investors and stakeholders. Looking ahead, FMS is well-positioned to expand its offerings, enter new markets, and improve patient outcomes, ensuring its continued success in the healthcare industry.